We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Health Canada routinely misses statutory deadlines for reviewing generic drugs, over-the-counter (OTC) formulations requiring clinical review and postmarket change submissions, the auditor general of Canada says.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor